The Budget Impact of Increased Use of Febuxostat in the Management of Gout: A US Health Plan Managed Care Pharmacy and Medical Costs Perspective

被引:5
|
作者
Smolen, Lee J. [1 ]
Gahn, James C. [1 ]
Mitri, Ghaith [2 ,3 ]
Shiozawa, Ald [2 ]
机构
[1] Med Decis Modeling Inc, 201 N Illinois St,Suite 1730, Indianapolis, IN 46204 USA
[2] Takeda Pharmaceut Int Inc, Deerfield, IL USA
[3] NaviHlth Inc, Brentwood, TN USA
关键词
allopurinol; budget impact analysis; febuxostat; gout; pharmaceutical; rheumatology; CHRONIC KIDNEY-DISEASE; ALLOPURINOL HYPERSENSITIVITY SYNDROME; OF-RHEUMATOLOGY GUIDELINES; SERUM URIC-ACID; CARDIOVASCULAR EVENTS; LOWERING THERAPY; HYPERURICEMIA; URATE; PROGRESSION; POPULATION;
D O I
10.1016/j.clinthera.2016.05.007
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Purpose: Gout is a chronic disease characterized by the deposition of urate crystals in the joints and throughout the body, caused by an excess burden of serum uric acid (sUA). The study estimates pharmacy and medical cost budgetary impacts of wider adoption by US payers of febuxostat, a urate-lowering therapy (ULT) for the treatment of gout. Methods: A US payer-perspective budget impact model followed ULT patients from a 1,000,000 member plan over 3 years. The current market share scenario, febuxostat (6%) and ULT allopurinol (94%), was compared with an 18% febuxostat market share. Data were implemented from randomized controlled trials, census and epidemiologic studies, and real-world database analyses. An innovation was the inclusion of gout-related chronic kidney disease costs. Cost results were estimated as annual and cumulative incremental costs, expressed as total costs, cost per member per month, and cost per treated member per month. Clinical results were also estimated. Findings: Increasing the febuxostat market share resulted in a 6.3% increase in patients achieving the sUA target level of <6.0 mg/dL and a 1.4% reduction in gout flares during the 3-year period. Total cost increased 1.4%, with a 49.9% increase in ULT costs, a 1.4% reduction in flare costs, a 1.2% reduction in chronic kidney disease costs, and a 2.8% reduction in gout care costs. The cumulative incremental costs were $1,307,425 in the first year, $1,939,016 through the second year, and $2,092,744 through the third year. By the third year, savings in medical costs offset most of the increase in treatment costs. Impacts on cumulative cost per member per month and cumulative cost per treated member per month followed the same pattern, with the highest impact in the first year and cumulative impacts declining during the 3-year period. The cumulative cost per member per month impact was estimated as $0.109, $0.081, and $0.058 and the cumulative cost per treated member per month impact was estimated as $12.416, $9.207, and $6.625 in the first year, through the second year, and through the third year, respectively. Implications: Expanding the febuxostat market share would result in improved clinical outcomes, but with an overall increase in costs over 3 years due to higher costs of treatment. By the third year, savings in medical costs, primarily in chronic kidney disease costs, would offset most of the increase in treatment costs. Expanded use of febuxostat in the treatment of all gout patients, independent of renal impairment status, should be considered based on improved clinical outcomes and longer-term medical cost savings associated with these improved outcomes. (C) 2016 Elsevier HS Journals, Inc. All rights reserved.
引用
收藏
页码:1710 / 1725
页数:16
相关论文
共 35 条
  • [1] Irritable bowel syndrome, health care use, and costs: A US managed care perspective
    Longstreth, GF
    Wilson, A
    Knight, K
    Wong, J
    Chiou, CF
    Barghout, V
    Frech, F
    Ofman, JJ
    [J]. AMERICAN JOURNAL OF GASTROENTEROLOGY, 2003, 98 (03): : 600 - 607
  • [2] Budget impact of adding lesinurad for second-line treatment of gout: a US health plan perspective
    Klein, Robert W.
    Kabadi, Shaum
    Cinfio, Frank N.
    Bly, Christopher A.
    Taylor, Douglas C. A.
    Szymanski, Keith A.
    [J]. JOURNAL OF COMPARATIVE EFFECTIVENESS RESEARCH, 2018, 7 (08) : 807 - 816
  • [3] The Few Who Use The Most: Costs Of Severe And Persistent Asthma In A Us Managed Care Plan
    Chastek, B.
    Korrer, S.
    Altan, A.
    Nagar, S. P.
    Dalal, A. A.
    [J]. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2015, 191
  • [4] Assessing the budget impact of drug-eluting stent adoption in a typical US managed care plan
    Clark, MA
    Lacey, MJ
    Cohen, DJ
    [J]. AMERICAN JOURNAL OF CARDIOLOGY, 2003, 92 (6A): : 25L - 25L
  • [5] The impact of low health literacy on the medical costs of Medicare managed care enrollees
    Howard, DH
    Gazmararian, J
    Parker, RM
    [J]. AMERICAN JOURNAL OF MEDICINE, 2005, 118 (04): : 371 - 377
  • [6] BUDGET IMPACT OF A FIXED -DOSE COMBINATION THERAPY OF LESINURAD AND ALL OPURINOL FOR SECOND -LINE GOUT THERAPY: A US COMMERCIAL HEALTH PLAN PERSPECTIVE
    Fu, A.
    Taylor, D.
    [J]. VALUE IN HEALTH, 2018, 21 : S193 - S193
  • [7] Health Plan Retention and Pharmacy Costs of Newly Diagnosed Patients with Chronic Kidney Disease in a Managed Care Population
    Kubacki, Maureen
    Carter, Chureen
    Herrera, Alan D. L.
    Wang, Jim
    Lopez, Janice M.
    Piech, Catherine T.
    [J]. AMERICAN HEALTH AND DRUG BENEFITS, 2009, 2 (06): : 283 - 290
  • [8] The Impact of an Online Disease Management Program on Medical Costs Among Health Plan Members
    Schwartz, Steven M.
    Day, Brian
    Wildenhaus, Kevin
    Silberman, Anna
    Wang, Chun
    Silberman, Jordan
    [J]. AMERICAN JOURNAL OF HEALTH PROMOTION, 2010, 25 (02) : 126 - 133
  • [9] Forgone Medical Care Associated With Increased Health Care Costs Among the US Heart Failure Population
    Thomas, Alexander
    Valero-Elizondo, Javier
    Khera, Rohan
    Warraich, Haider J.
    Reinhardt, Samuel W.
    Ali, Hyeon-Ju
    Nasir, Khurram
    Desai, Nihar R.
    [J]. JACC-HEART FAILURE, 2021, 9 (10) : 710 - 719
  • [10] Impact of a Novel Cost-Saving Pharmacy Program on Pregabalin Use and Health Care Costs
    Martin, Carolyn
    Odell, Kevin
    Cappelleri, Joseph C.
    Bancroft, Tim
    Halpern, Rachel
    Sadosky, Alesia
    [J]. JOURNAL OF MANAGED CARE & SPECIALTY PHARMACY, 2016, 22 (02): : 132 - 144